Clinical trial · Interventional
ATAC - Arimidex, Tamoxifen Alone or in Combination
A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer
NCT00849030CI-TRIAL-00007095completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anastozole (Arimidex) | Drug | — | UNRESOLVED |
| Anastozole (Arimidex) placebo | Drug | — | UNRESOLVED |
| Tamoxifen (Nolvadex) | Drug | Tamoxifen | ALIAS |
| Tamoxifen (Nolvadex) placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Arimidex 1mg + Nolvadex placebo
- interventionNames
- Drug: Anastozole (Arimidex)
- Drug: Tamoxifen (Nolvadex) placebo
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- Arimidex placebo + Nolvadex 20mg
- interventionNames
- Drug: Tamoxifen (Nolvadex)
- Drug: Anastozole (Arimidex) placebo
- type
- ACTIVE_COMPARATOR
- label
- 3
- description
- Arimidex 1mg + Nolvadex 20mg
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically proven operable invasive breast cancer * Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy * Women defined as post-menopausal Exclusion Criteria: * Patients in whom there is any clinical evidence of metastatic disease * Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements * Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment
References
Publications (0)
Data not yet available
No reference posted for this study.